Leading contract management platform Concord raised $25 million in a series B round.

News

The San Francisco-based contract management platform, founded by Mathieu Lhoumeau and Florian Parain, has secured its latest round of funding led by a new investor, Tenaya Capital, joined by previous investors Alven and Charles River Ventures.

Currently the fastest-growing contract management platform on the market, Concord has secured $25 million in Series B funding with the help of previous investors Alven and CRV, as well as a new investor Tenaya Capital, to continue transforming how businesses operate.

 

This new round of funding happens after the company announced 300% YoY revenue growth and a doubling of its enterprise customer base in 2018. Kickstarter, Newell brands, Barracuda Networks, Bitdefender, Rent the Runway, and Sizzling Platter are among the 180,000 companies that are using the Concord platform.

 

Concord provides a collaborative, intelligent environment where business contracts can be managed, driving collaboration across an organization’s legal, finance, procurement, and sales teams. With all parties and documents centralized, the friction and visibility issues that are often associated with contact creation and renewal can be eliminated. Concord will grow its engineering, HR, sales and marketing teams, in addition to pursuing its international expansion and the platform development.

 

As the Concord’s first institutional investor since 2015, Alven is pleased to join Tenaya Capital and Charles River Ventures to support the company in their expansion.

 


Share

Skarlett Raises €8 Million Seed Round to Reinvent Personal Finance for the 60+ Generation

Skarlett, the marketplace dedicated to the financial needs of those over 60, today announces an €8 million seed funding round. The round…

Read

Carbon credits, built for business: Riverse €5M seed round

Riverse raised €5 million in seed funding to make carbon credits work for real companies and the real challenges they face. Alven…

Read

Okeiro raises €10 Million to accelerate development of its Precision Medicine platform for Transplantation and Chronic Diseases

Okeiro, a company specializing in precision medicine for transplantation and advanced chronic diseases, today announces a €10 million funding round to accelerate…

Read